ES2262174T3 - Forma de dosificacion y procedimiento de administracion de medicamentos. - Google Patents
Forma de dosificacion y procedimiento de administracion de medicamentos.Info
- Publication number
- ES2262174T3 ES2262174T3 ES97910713T ES97910713T ES2262174T3 ES 2262174 T3 ES2262174 T3 ES 2262174T3 ES 97910713 T ES97910713 T ES 97910713T ES 97910713 T ES97910713 T ES 97910713T ES 2262174 T3 ES2262174 T3 ES 2262174T3
- Authority
- ES
- Spain
- Prior art keywords
- drug
- hours
- dose
- tolerance
- methylphenidate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 31
- 239000002552 dosage form Substances 0.000 title claims description 46
- 238000001647 drug administration Methods 0.000 title description 8
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims description 143
- 229940079593 drug Drugs 0.000 claims description 136
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims description 41
- 229960001344 methylphenidate Drugs 0.000 claims description 41
- 230000002459 sustained effect Effects 0.000 claims description 33
- 230000001154 acute effect Effects 0.000 claims description 20
- 230000007423 decrease Effects 0.000 claims description 16
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 15
- 239000002245 particle Substances 0.000 claims description 13
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 10
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 8
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 8
- 230000006735 deficit Effects 0.000 claims description 7
- 238000011161 development Methods 0.000 claims description 7
- 229940025084 amphetamine Drugs 0.000 claims description 6
- 229960000632 dexamfetamine Drugs 0.000 claims description 6
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims description 6
- 229960001252 methamphetamine Drugs 0.000 claims description 6
- FRCFWPVMFJMNDP-UHFFFAOYSA-N n-propan-2-ylaniline Chemical compound CC(C)NC1=CC=CC=C1 FRCFWPVMFJMNDP-UHFFFAOYSA-N 0.000 claims description 6
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 claims description 6
- 229960000761 pemoline Drugs 0.000 claims description 6
- 230000033764 rhythmic process Effects 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 5
- 208000013403 hyperactivity Diseases 0.000 claims description 2
- 238000012423 maintenance Methods 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 49
- 230000001174 ascending effect Effects 0.000 description 23
- 238000013268 sustained release Methods 0.000 description 13
- 239000012730 sustained-release form Substances 0.000 description 13
- 210000003169 central nervous system Anatomy 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 10
- 230000006399 behavior Effects 0.000 description 8
- 230000001684 chronic effect Effects 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 206010052804 Drug tolerance Diseases 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 230000007012 clinical effect Effects 0.000 description 4
- 210000000653 nervous system Anatomy 0.000 description 4
- 230000000630 rising effect Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 206010027374 Mental impairment Diseases 0.000 description 2
- 239000002269 analeptic agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 239000003368 psychostimulant agent Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 241001074085 Scophthalmus aquosus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000005978 brain dysfunction Effects 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 239000003874 central nervous system depressant Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- JUMYIBMBTDDLNG-OJERSXHUSA-N hydron;methyl (2r)-2-phenyl-2-[(2r)-piperidin-2-yl]acetate;chloride Chemical compound Cl.C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 JUMYIBMBTDDLNG-OJERSXHUSA-N 0.000 description 1
- 230000001660 hyperkinetic effect Effects 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- DUGOZIWVEXMGBE-OLZOCXBDSA-N methyl (S)-phenyl[(R)-piperidin-2-yl]acetate Chemical compound C([C@@H]1[C@@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 DUGOZIWVEXMGBE-OLZOCXBDSA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 229940000041 nervous system drug Drugs 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000001003 psychopharmacologic effect Effects 0.000 description 1
- 229940099204 ritalin Drugs 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2872696P | 1996-09-30 | 1996-09-30 | |
| US28726P | 1996-09-30 | ||
| US3051496P | 1996-11-12 | 1996-11-12 | |
| US30514P | 1996-11-12 | ||
| US4412197P | 1997-04-22 | 1997-04-22 | |
| US44121P | 1997-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2262174T3 true ES2262174T3 (es) | 2006-11-16 |
Family
ID=27363329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES97910713T Expired - Lifetime ES2262174T3 (es) | 1996-09-30 | 1997-09-16 | Forma de dosificacion y procedimiento de administracion de medicamentos. |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0932388B1 (enExample) |
| JP (3) | JP4714313B2 (enExample) |
| CN (1) | CN1231603A (enExample) |
| AT (1) | ATE321529T1 (enExample) |
| AU (1) | AU4801497A (enExample) |
| CA (1) | CA2264852C (enExample) |
| DE (1) | DE69735581T2 (enExample) |
| DK (1) | DK0932388T5 (enExample) |
| ES (1) | ES2262174T3 (enExample) |
| PT (1) | PT932388E (enExample) |
| WO (1) | WO1998014168A2 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6440457B1 (en) | 1993-05-27 | 2002-08-27 | Alza Corporation | Method of administering antidepressant dosage form |
| US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
| DE69735581T2 (de) * | 1996-09-30 | 2007-01-25 | Alza Corp., Palo Alto | Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung |
| US6919373B1 (en) | 1996-11-12 | 2005-07-19 | Alza Corporation | Methods and devices for providing prolonged drug therapy |
| US6962997B1 (en) | 1997-05-22 | 2005-11-08 | Celgene Corporation | Process and intermediates for resolving piperidyl acetamide steroisomers |
| AU2004200938B2 (en) * | 1998-06-03 | 2006-09-14 | Alza Corporation | Methods and devices for providing prolonged drug therapy |
| KR100827254B1 (ko) * | 1998-06-03 | 2008-05-07 | 알자 코포레이션 | 연장된 약물 치료를 제공하기 위한 방법 및 장치 |
| AU2012232984B2 (en) * | 1998-06-03 | 2015-10-29 | Alza Corporation | Methods and devices for providing prolonged drug therapy |
| ATE277594T1 (de) * | 1998-06-03 | 2004-10-15 | Alza Corp | Vorrichtungen um eine verlängerte medikamententherapie zu erreichen |
| US6322819B1 (en) | 1998-10-21 | 2001-11-27 | Shire Laboratories, Inc. | Oral pulsed dose drug delivery system |
| KR20070051953A (ko) | 1998-11-02 | 2007-05-18 | 엘란 코포레이션, 피엘씨 | 다입자 변형 방출 조성물 |
| US7083808B2 (en) | 1998-12-17 | 2006-08-01 | Euro-Celtique S.A. | Controlled/modified release oral methylphenidate formulations |
| US6673367B1 (en) | 1998-12-17 | 2004-01-06 | Euro-Celtique, S.A. | Controlled/modified release oral methylphenidate formulations |
| US6419960B1 (en) | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
| US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
| KR20020059653A (ko) | 1999-10-29 | 2002-07-13 | 그린 마틴, 브라이언 쥐 테슬리 | 서방성 하이드로코돈 제형 |
| US6733783B2 (en) | 2000-10-30 | 2004-05-11 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
| US7300668B2 (en) | 2001-10-29 | 2007-11-27 | Massachusetts Institute Of Technology | System for manufacturing controlled release dosage forms, such as a zero-order release profile dosage form manufactured by three-dimensional printing |
| JP2010229140A (ja) * | 2002-02-22 | 2010-10-14 | Shire Llc | 活性物質送達系及び活性物質を保護し投与する方法 |
| US20050232995A1 (en) | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
| US7988993B2 (en) | 2002-12-09 | 2011-08-02 | Andrx Pharmaceuticals, Inc. | Oral controlled release dosage form |
| AU2005271522B2 (en) * | 2004-08-04 | 2011-02-10 | Alza Corporation | Sustained drug release composition demonstrating an ascending zero order release pattern, methods of manufacturing such a composition |
| DK1791530T3 (da) | 2004-08-23 | 2008-10-27 | Pejo Iserlohn Heilmittel Und D | Farmaceutisk komposition indeholdende et psykostimulerende middel |
| US8541026B2 (en) | 2004-09-24 | 2013-09-24 | Abbvie Inc. | Sustained release formulations of opioid and nonopioid analgesics |
| DK2018160T3 (da) | 2006-03-16 | 2012-02-06 | Tris Pharma Inc | Modificeret depotformuleringer indeholdende lægemiddel-ionbytterharpikskomplekser |
| US8846100B2 (en) | 2006-05-12 | 2014-09-30 | Shire Llc | Controlled dose drug delivery system |
| EP1920768A1 (en) * | 2006-11-10 | 2008-05-14 | Abbott GmbH & Co. KG | Solid dosage form with a film containing an active substance, as well as its method of production |
| JP2011511782A (ja) | 2008-02-12 | 2011-04-14 | アボット・ラボラトリーズ | 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途 |
| US9603809B2 (en) | 2011-03-23 | 2017-03-28 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
| US10905652B2 (en) | 2011-03-23 | 2021-02-02 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US10292937B2 (en) | 2011-03-23 | 2019-05-21 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
| US8916588B2 (en) | 2011-03-23 | 2014-12-23 | Ironshore Pharmaceuticals & Development, Inc. | Methods for treatment of attention deficit hyperactivity disorder |
| US9283214B2 (en) | 2011-03-23 | 2016-03-15 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| EP4316488A3 (en) | 2011-03-23 | 2024-02-28 | Ironshore Pharmaceuticals & Development, Inc. | Methods and compositions for treatment of attention deficit disorder |
| US8927010B2 (en) | 2011-03-23 | 2015-01-06 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US9119809B2 (en) | 2011-03-23 | 2015-09-01 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US11241391B2 (en) | 2011-03-23 | 2022-02-08 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US9498447B2 (en) | 2011-03-23 | 2016-11-22 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| CA2880456A1 (en) | 2012-08-15 | 2014-02-20 | Tris Pharma, Inc. | Methylphenidate extended release chewable tablet |
| WO2014174387A1 (en) | 2013-03-29 | 2014-10-30 | Wockhardt Limited | Modified release pharmaceutical compositions of dexmethylphenidate or salts thereof |
| DE102013014417A1 (de) | 2013-08-29 | 2015-03-05 | Klinipharm Gmbh | Schwammkollagen umfassende Zubereitungen mit definiertem in vivo-Freisetzungsprofil vor allem im Colon, deren Herstellung und Verwendung |
| WO2015188092A1 (en) * | 2014-06-06 | 2015-12-10 | Rhodes Pharmaceuticals, L.P. | Methods for treating attention deficit hyperactivity disorder with methylphenidate |
| CA2902911C (en) | 2014-10-31 | 2017-06-27 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
| US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
| US12458592B1 (en) | 2017-09-24 | 2025-11-04 | Tris Pharma, Inc. | Extended release amphetamine tablets |
| US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
| US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2738303A (en) * | 1952-07-18 | 1956-03-13 | Smith Kline French Lab | Sympathomimetic preparation |
| US3400197A (en) * | 1965-01-26 | 1968-09-03 | Robins Co Inc A H | Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules |
| US3625214A (en) * | 1970-05-18 | 1971-12-07 | Alza Corp | Drug-delivery device |
| DE2336218C3 (de) * | 1973-07-17 | 1985-11-14 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Orale Arzneiform |
| US4304591A (en) * | 1978-01-25 | 1981-12-08 | Ciba-Geigy Corporation | Water-insoluble hydrophilic copolymers used as carriers for medicaments and pesticides |
| EP0094123A3 (en) * | 1982-05-06 | 1984-07-25 | THE PROCTER & GAMBLE COMPANY | Therapeutic granules |
| DE3678644D1 (de) * | 1985-08-16 | 1991-05-16 | Procter & Gamble | Wirkstoffpartikel mit sowohl kontinuierlicher als auch schneller freisetzung. |
| LU86077A1 (fr) * | 1985-09-18 | 1987-04-02 | Pharlyse Sa | Nouvelles formes galeniques du verapamil,leur fabrication et medicaments contenant ces nouvelles formes galeniques |
| DE3822095A1 (de) * | 1988-06-30 | 1990-01-04 | Klinge Co Chem Pharm Fab | Neue arzneimittelformulierung sowie verfahren zu deren herstellung |
| SE509029C2 (sv) * | 1988-08-16 | 1998-11-30 | Ss Pharmaceutical Co | Långtidsverkande diklofenak-natriumpreparat |
| US4927639A (en) * | 1989-02-02 | 1990-05-22 | Warner-Lambert Company | Modified release gemfibrozil composition |
| FI93924C (fi) * | 1991-09-17 | 1995-06-26 | Martti Lauri Antero Marvola | Menetelmä säädellysti lääkeainetta vapauttavan valmisteen valmistamiseksi |
| ATE183642T1 (de) * | 1991-10-04 | 1999-09-15 | Yoshitomi Pharmaceutical | Tablette mit verzögerter freisetzung |
| ES2194210T3 (es) * | 1996-08-16 | 2003-11-16 | Alza Corp | Forma de dosificacion para suministrar una dosis ascendente de farmaco. |
| DE69735581T2 (de) * | 1996-09-30 | 2007-01-25 | Alza Corp., Palo Alto | Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung |
-
1997
- 1997-09-16 DE DE69735581T patent/DE69735581T2/de not_active Expired - Lifetime
- 1997-09-16 AU AU48014/97A patent/AU4801497A/en not_active Abandoned
- 1997-09-16 PT PT97910713T patent/PT932388E/pt unknown
- 1997-09-16 WO PCT/US1997/016599 patent/WO1998014168A2/en not_active Ceased
- 1997-09-16 AT AT97910713T patent/ATE321529T1/de active
- 1997-09-16 JP JP51658798A patent/JP4714313B2/ja not_active Expired - Lifetime
- 1997-09-16 EP EP97910713A patent/EP0932388B1/en not_active Expired - Lifetime
- 1997-09-16 DK DK97910713.3T patent/DK0932388T5/da active
- 1997-09-16 CA CA002264852A patent/CA2264852C/en not_active Expired - Lifetime
- 1997-09-16 CN CN97198342A patent/CN1231603A/zh active Pending
- 1997-09-16 ES ES97910713T patent/ES2262174T3/es not_active Expired - Lifetime
-
2010
- 2010-05-12 JP JP2010110166A patent/JP5697893B2/ja not_active Expired - Lifetime
-
2013
- 2013-10-11 JP JP2013213661A patent/JP2014028854A/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA2264852A1 (en) | 1998-04-09 |
| DK0932388T5 (da) | 2011-06-27 |
| CA2264852C (en) | 2005-11-01 |
| DE69735581T2 (de) | 2007-01-25 |
| EP0932388A2 (en) | 1999-08-04 |
| ATE321529T1 (de) | 2006-04-15 |
| JP5697893B2 (ja) | 2015-04-08 |
| EP0932388B1 (en) | 2006-03-29 |
| WO1998014168A3 (en) | 1998-07-30 |
| DK0932388T3 (da) | 2006-07-17 |
| JP2014028854A (ja) | 2014-02-13 |
| CN1231603A (zh) | 1999-10-13 |
| DE69735581D1 (de) | 2006-05-18 |
| AU4801497A (en) | 1998-04-24 |
| JP2001501223A (ja) | 2001-01-30 |
| HK1127997A1 (en) | 2009-10-16 |
| PT932388E (pt) | 2006-07-31 |
| JP2010195822A (ja) | 2010-09-09 |
| WO1998014168A2 (en) | 1998-04-09 |
| JP4714313B2 (ja) | 2011-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2262174T3 (es) | Forma de dosificacion y procedimiento de administracion de medicamentos. | |
| Seidel et al. | Buspirone: an anxiolytic without sedative effect | |
| US20050031688A1 (en) | Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration | |
| Weeks et al. | Postural vertigo due to trigger areas in the sternocleidomastoid muscle | |
| AU2021258135A1 (en) | Methods for treating mild traumatic brain injury, post traumatic stress disorder and mild traumatic brain injury | |
| AU2010282660A1 (en) | Methods for iontophoretically treating nausea and migraine | |
| Graff-Radford | Headache problems that can present as toothache | |
| US20200306227A1 (en) | Melatonin mini-tablets and method of manufacturing the same | |
| Bensimon et al. | Antagonism by modafinil of the psychomotor and cognitive impairment induced by sleep-deprivation in 12 healthy volunteers | |
| KR20080028480A (ko) | 티자니딘 조성물 및 이 조성물을 사용하는 치료 방법 | |
| Crowley et al. | Bedtime flurazepam and the human circadian rhythm of spontaneous motility | |
| Oswald | Assessment of insomnia | |
| US10849856B2 (en) | Melatonin mini-tablets and method of manufacturing the same | |
| CA2515884C (en) | Dosage form and method for administering drug | |
| Paymaster | Section C Lorazepam in anaesthesia | |
| EP1690531A2 (en) | Dosage form and method for administering drug | |
| HK40120004A (en) | Melatonin mini-tablets and method of manufacturing the same | |
| Gottfries | Pharmacological treatment of sleep disorders | |
| Machleidt et al. | Anxiety processes in the EEG | |
| HK1127997B (en) | Dosage form and method for administering drug | |
| Brokloff | Effect of prednisolone on the systemic response and wound healing after colonic surgery: Schulze S, Andersen J, Nørgaard H, et al. Arch Surg 132: 129, 1997 | |
| Holloway | Reliability of disposable intraoperative facial nerve stimulators: Randal D, Webster D, Hunsaker D. Laryngoscope 107: 192, 1997 | |
| Salinas et al. | Prescribing nicotine substitutes for tobacco cessation: Considerations and contraindications | |
| Nakajima | Basic study of cancer chemotherapy with magnetoliposomes containing CDDP. 1: Preparation of magnetoliposomes and their effects on cultured tumor cells: Jinbu Y, Akasaka Y, Ito H, et al. Jpn J Oral Maxillofac Surg 43: 55, 1997 |